The Department of Defense (DoD) is offering this grant to support the rapid implementation of clinical trials. This grant is for projects with the potential to significantly impact diseases or conditions addressed in the Congressionally directed FY13 PRMRP Topic Areas. Eligible trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Projects can range from small proof-of-concept (e.g., pilot, first-in-human) trials to large-scale studies determining efficacy in relevant patient populations. All proposed work must be responsive to the healthcare needs of military service members, Veterans, and/or beneficiaries, though the direct use of military populations is not a requirement for the research.
Opportunity ID: 234533
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-13-PRMRP-CTA |
| Funding Opportunity Title: | DoD Peer Reviewed Medical Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 14, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Oct 08, 2013 |
| Current Closing Date for Applications: | Oct 08, 2013 |
| Archive Date: | Nov 07, 2013 |
| Estimated Total Program Funding: | $6,600,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on a disease or condition addressed in at least one of the Congressionally directed FY13 PRMRP Topic Areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance,and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept (i.e., pilot, first in human, or Phase 0) trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. All studies must be responsive to the health care needs of the military service members, Veterans, and/or beneficiaries; however, the use of military populations is not required. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
301-682-5507; help@cdmrp.org
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 234533 Full Announcement-1 -> fy13 ind-ide documentation fillable form.pdf
Folder 234533 Full Announcement-1 -> w81xwh-13-prmrp-cta.pdf
Folder 234533 Revised Full Announcement-1 -> w81xwh-13-prmrp-cta revised.pdf
Packages
| Agency Contact Information: | 301-682-5507; help@cdmrp.org Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00177730 | May 14, 2013 | Oct 09, 2013 | View |
Package 1
Mandatory forms
234533 RR_SF424_1_2-1.2.pdf
234533 PerformanceSite_1_4-1.4.pdf
234533 RR_Budget-1.1.pdf
234533 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
234533 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
